HB1801

· CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for HB1801, covering 2023-11-07 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer [Phase 3]

See pricing